OnCo
journalsJournal

Journal of Nuclear Medicine

aka JNM, J Nucl Med

The Journal of Nuclear Medicine is the SNMMI's journal and the core venue for PET tracers and radioligand therapy: PSMA and somatostatin imaging, lutetium and actinium dosimetry, and theranostics trials.

The Journal of Nuclear Medicine appears monthly and publishes first-in-human tracer studies, PSMA PET diagnostic accuracy trials, radioligand-therapy dosimetry and outcomes (lutetium-177 PSMA and DOTATATE, actinium-225), and SNMMI procedure standards. Articles become free to read after a delay; the SNMMI annual meeting abstracts are published as a supplement.

Publisher
Society of Nuclear Medicine and Molecular Imaging · Society of Nuclear Medicine and Molecular Imaging
Scope
nuclear medicine
Access model
hybrid
Founded
1960
ISSN
0161-5505

People

4top
Clemens Kratochwil
Nuclear medicine physician, Heidelberg University Hospital
Targeted alpha therapyPSMA radioligandsDosimetry

Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.

Frederik Giesel
Director of Nuclear Medicine, University Hospital Düsseldorf; formerly Heidelberg
Molecular imagingFAPI PETPSMA theranostics

Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.

Jeremie Calais
Associate Professor; Director, Clinical Research Program, Ahmanson Translational Theranostics Division, UCLA
PSMA PETRadioligand therapyClinical trials

Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.

Uwe Haberkorn
Head of Nuclear Medicine, Heidelberg University Hospital and DKFZ
Nuclear medicineFAP-targeted radiopharmaceuticalsTheranostics

Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.

Connected

2top

Pages like this

not linked directly; found by shared links

technologies

1
Radioligand therapy (beta emitters)

collections

1
SNMMI Annual Meeting